IBI-3012

N/A

Report date: 2026/04/07 20:00:20

Base Information

Drug NameIBI-3012

Drug Alias NameIBI3012IBI-3012

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucagon receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor antagonists

TargetsGlucagon-like peptide 1 receptorGlucagon receptorGlucose-Dependent Insulinotropic Polypeptide Receptor

Therapy Area/IndicationsObesityDiabetes MellitusMetabolic Dysfunction-Associated Steatotic Liver Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesInnovent Biologics(Suzhou) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsObesityDiabetes MellitusMetabolic Dysfunction-Associated Steatotic Liver Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A